COVID Science Communication


Threads with >100,000 views: Estimate of vaccine efficacy in blocking infection/transmission (2,260K views),  COVID-19 Control (471K), Asymptomatic transmission (470K), Misleading Stanford Seroprevalence study (309K), Pfizer efficacy severe infections (461K), Vaccination reducing transmission vs disease (288K), 3’ vs 6’ in schools (388K), Viral loads and transmission (186K), Review vaccine efficacy transmission (114K), Virus variant spread in US (135K), Patterns of exposure (188K), How long are you infectious? (126K), Design of Seroprevalence studies (159K), Herd Immunity influencing transmission (143K), Herd immunity misleading study (137K), Silent spreading by vaccinated people (185K)

Threads with 50,000-100,000 views: Clusters of cases (84K views), Reconciling low seroprevalence studies (50K), What a COVID-19 test can tell you (50K), How testing and infectiousness are correlated (70K), Aerosol transmission (53K), Herd Immunity (82K), Transmission of children vs adults (50K), Transmission at a children’s camp (78K), Transmission on train (50K), Early review of immunity (50K), Transmission on airplane (50K), Household transmission (89K), Vaccines reducing infectiousness (73K), Vaccine priorities (61K), Age specific case and death data (67K), Novavax vaccine (52K), Non-100% effectiveness of vaccines (62K), Non-100% effectiveness again (85K), Variant spread Brazil (50K), Variant vaccine immune evasion S Africa (72K), Vaccine effectiveness mild vs severe (52K), Herd immunity threshold (74K), Test sensitivity over time (90K)